ALACHUA, FL, September 20, 2016 (BUSINESSWIRE) - Nanotherapeutics, Inc., a contract development and manufacturing organization (CDMO), announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the company a contract for advanced biologics manufacturing services as part of a multiple award IDIQ (Indefinite Delivery/Indefinite Quantity) pool. The contract has a maximum ceiling of $159.4 million and a performance period of up to 10 years.

Read the Full Article at BUSINESSWIRE

Former Gates Foundation and Baxter Executive Peter H. Khoury, Ph.D. Joins Nanotherapeutics as Chief Commercial Officer ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a contract development and manufacturing organization (CDMO), announced today that Peter Khoury, [...]

Nanotherapeutics Closes Sale-Leaseback Financing with Senior Housing Properties Trust for the Company’s New Advanced Development and Manufacturing Facility in Alachua, FL ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, an integrated biopharmaceutical company with a focus on [...]

Nanotherapeutics CEO is Guest Panelist at FBR’s Health Series Conference ALACHUA, FL April 22, 2016. On April 20, FBR hosted a thematic conference featuring 16 guest speakers in four panels to discuss [...]

Governor Scott Highlights Recent Job Growth at Nanotherapeutics, Inc. ALACHUA, Fla. – Today, Governor Rick Scott highlighted recent job growth at Nanotherapeutics, Inc., a biopharmaceutical company. In 2013, Governor Scott announced that [...]

On March 21st, 2016, Nanotherapeutics will host an interactive mini-symposium devoted to the use of Monoclonal Antibody Technology for Development of Medical Countermeasures.  Specific emphasis will be on the development of monoclonal antibodies against Botulinum Neurotoxins, as part of the Advanced Development and Manufacturing of Antibody Technologies (ADAMANT) concept.  This meeting will take place at the Nanotherapeutics-Maryland office located at 8490 Progress Drive, Suite 150, Frederick, MD 21701.  The meeting will begin at 10:00 a.m. and will conclude at 1:00 p.m.